Skip to main content
. Author manuscript; available in PMC: 2025 Jul 1.
Published in final edited form as: J Thromb Haemost. 2024 Apr 2;22(7):1984–1996. doi: 10.1016/j.jtha.2024.03.020

Table 4.

Biomarkers associated with deep vein thrombosis risk in acute leukemia.

Biomarker# Univariable Multivariable analysis*
sHR (95% CI) sHR (95% CI)
EVTF activity 1.11 (0.46 - 2.71) 1.15 (0.46 - 2.92)
PS + EVs 1.09 (0.45 - 2.64) 1.13 (0.47 - 2.71)
cfDNA 0.56 (0.25 - 1.26) 0.61 (0.26 - 1.41)
H3Cit-DNA complexes 0.75 (0.32 - 1.77) 0.66 (0.28 - 1.56)
PAP 0.75 (0.32 - 1.74) 0.87 (0.36 - 2.10)
tPA 0.53 (0.24 - 1.20) 0.48 (0.19 - 1.24)
PAI-1 2.43 (0.83 - 7.13) 3.00 (0.95 - 9.47)
D-dimer 0.72 (0.31 - 1.69) 0.98 (0.36 - 2.66)
Fibrinogen 0.81 (0.35 - 1.85) 0.60 (0.26 - 1.42)
PT 1.46 (0.58 - 3.68) 1.51 (0.62 - 3.65)
PTT 1.38 (0.55 - 3.48) 1.30 (0.49 - 3.44)
WBC count 0.96 (0.41 - 2.24) 0.80 (0.34 - 1.92)
Peripheral blood blast cell 0.57 (0.23 - 1.39) 0.80 (0.30 - 2.14)
Platelet count 1.46 (0.58 - 3.69) 1.49 (0.57 - 3.89)
Creatinine 1.11 (0.44 - 2.79) 1.39 (0.51 - 3.79)
Hemoglobin 1.50 (0.59 - 3.80) 1.38 (0.52 - 3.64)
LDH 0.90 (0.38 - 2.13) 0.79 (0.33 - 1.89)
#

Biomarkers were considered as tertiles, and third and second tertile distributions were compared to the first tertile, and adjusted for clinically relevant covariates in multivariable models.

*

Multivariable model was adjusted for age, sex, race/ethnicity, leukemia type, body mass index, history of venous thromboembolism and comorbidities.

Abbreviations: cfDNA, cell-free DNA; EVTF, extracellular vesicle tissue factor; H3Cit-DNA, citrullinated histone H3-DNA; LDH, lactate dehydrogenase; PAI-1, plasminogen activator inhibitor-1; PAP, plasmin-antiplasmin complex; PS+EVs, phosphatidylserine-positive extracellular vesicles; PT, prothrombin time; PTT, partial thromboplastin time; tPA, tissue plasminogen activator; WBC, white blood cell; 95% CI, 95% confidence interval